Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1422142/000156459018005868/arpo-10k_20171231.htm
SEC Filings
ARPO Annual Reports
ARPO Quarterly Reports
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2019
10-Q Quarterly Report November 2018
10-Q Quarterly Report August 2018
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2019
10-Q Quarterly Report November 2018
10-Q Quarterly Report August 2018
ARPO Corporate News
Bylaw Change
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales August 2021
Financial Exhibit
New Agreement August 2021
Vote of Security Holders August 2021
Earnings Release
Financial Exhibit August 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders July 2021
Financial Exhibit
Regulated Disclosure June 2021
Earnings Release
Financial Exhibit May 2021
Bylaw Change
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales May 2021
Event for Officers
Financial Exhibit April 2021
Earnings Release
Financial Exhibit March 2021
Bylaw Change
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales
Change in Assets
Change in Control
Code of Ethics Change
Event for Officers
Financial Exhibit
New Agreement
Security Holders Change
Unregistered Sales
August 2021
Financial Exhibit
New Agreement
New Agreement
August 2021
Vote of Security Holders
August 2021
Earnings Release
Financial Exhibit
Financial Exhibit
August 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders
Regulated Disclosure
Vote of Security Holders
July 2021
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
June 2021
Earnings Release
Financial Exhibit
Financial Exhibit
May 2021
Bylaw Change
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales
Change in Control
Event for Officers
Financial Exhibit
New Agreement
Regulated Disclosure
Unregistered Sales
May 2021
Event for Officers
Financial Exhibit
Financial Exhibit
April 2021
Earnings Release
Financial Exhibit
Financial Exhibit
March 2021
Last10K.com | 10-K Annual Report Thu Mar 15 2018
Exhibit 99.1
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track
Conference Call and Webcast Today, March 13th at 8:30 a.m. ET
CINCINNATI— Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017.
“Over the past year, Aerpio has made tremendous progress in the development of AKB-9778, our first-in- class Tie2-activator,” said Stephen Hoffman, MD, PhD, Chief Executive Officer of Aerpio. “In June 2017, we initiated our TIME-2b Phase 2b study in patients with non-proliferative diabetic retinopathy (NPDR). The ability to delay or reverse the progression of NPDR to sight-threatening conditions, such as proliferative diabetic retinopathy and diabetic macular edema, is a significant unmet medical need. We have been very encouraged by the clinical community’s interest in AKB-9778’s differentiated mechanism of action, its subcutaneous route of administration, and potential to treat multiple diabetic vascular comorbidities. In fact, we announced last month that we had completed enrollment in TIME-2b three months earlier than originally projected. We also recently reported preliminary data supporting the potential of AKB-9778 to protect the kidney vasculature in patients with diabetes. Additionally, based on findings from our previous Phase 2 trial with AKB-9778, we plan to begin clinical development for an eye drop formulation of AKB-9778 to treat primary open angle glaucoma within the next year.”
Recent Company Highlights
| • | Completed enrollment in the TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of the Company’s lead candidate, AKB-9778, for patients with moderate-to- severe NPDR. |
| • | Presented promising preliminary renal function data from the Company’s Phase 2a TIME-2 clinical trial at the Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury. |
| • | Successfully completed pre-IND meeting with the FDA for AKB-4924, a once-daily, oral HIF-1α stabilizer for treatment of ulcerative colitis, a form of inflammatory bowel disease. |
The following information was filed by Aerpio Pharmaceuticals, Inc. (ARPO) on Tuesday, March 13, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Aerpio Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aerpio Pharmaceuticals, Inc..
Assess how Aerpio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Aerpio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss (unaudited)
Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders' Equity (deficit)
Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders' Equity (deficit) (parenthetical)
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (tables)
Accounts Payable And Accrued Expenses - Schedule Of Accounts Payable And Accrued Expenses (details)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Schedule Of Future Payments Related To Operating Leases (detail)
Common Stock
Common Stock - Additional Information (detail)
Employee Bonus Plan
Employee Bonus Plan - Additional Information (detail)
Employee Retirement Plan
Employee Retirement Plan - Additional Information (detail)
Employee Stock Purchase Plan
Employee Stock Purchase Plan - Additional Information (detail)
Furniture And Equipment
Furniture And Equipment (tables)
Furniture And Equipment - Summary Of Components Of Furniture And Equipment (detail)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Schedule Of Reconciliation Of Statutory Federal Income Tax (detail)
Income Taxes - Schedule Of Significant Components Of Deferred Tax Assets And Liabilities (detail)
Nature Of Organization And Operations
Nature Of Organization And Operations - Additional Information (detail)
Net Loss Per Share Attributable To Common Stockholders
Net Loss Per Share Attributable To Common Stockholders (tables)
Net Loss Per Share Attributable To Common Stockholders - Schedule Of Computation Of Basic And Diluted Net Loss Per Share (detail)
Net Loss Per Share Attributable To Common Stockholders - Schedule Of Weighted Average Common Stock Equivalents Excluded From Calculation Of Diluted Net Loss Per Share (detail)
Notes Payable To Investors
Notes Payable To Investors - Additional Information (detail)
Preferred Stock
Preferred Stock - Additional Information (detail)
Quarterly Results (unaudited)
Quarterly Results (unaudited) (tables)
Related-party Arrangements
Related-party Arrangements (tables)
Related-party Arrangements - Summary Of Activities Included In Statements Of Operations And Comprehensive Loss (detail)
Stock-based Compensation
Stock-based Compensation (tables)
Stock-based Compensation - Additional Information (detail)
Stock-based Compensation - Stock Options Valuation Assumptions (detail)
Stock-based Compensation - Summary Of Recognized Compensation Cost Related To Employee And Non-employee Stock-based Compensation Activity (detail)
Stock-based Compensation - Summary Of Restricted Stock Activity (detail)
Stock-based Compensation - Summary Of Stock Option Activity (detail)
Summary Of Quarterly Results (unaudited) (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Additional Information (detail)
Summary Of Significant Accounting Policies - Schedule Of Assets Measured On Recurring Basis (detail)
Material Contracts, Statements, Certifications & more
Aerpio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ARPO
CIK: 1422142
Form Type: 10-K Annual Report
Accession Number: 0001564590-18-005868
Submitted to the SEC: Thu Mar 15 2018 5:00:15 PM EST
Accepted by the SEC: Thu Mar 15 2018
Period: Sunday, December 31, 2017
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/arpo/0001564590-18-005868.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...